CoChat

Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice

Open access
Mayorandan, Sebene, Meyer, Uta, Gokcay, Gülden, Segarra, Nuria Garcia, de Baulny, Hélène Ogier, van Spronsen, Francjan, Zeman, Jiri, de Laet, Corinne, Spiekerkoetter, Ute, Thimm, Eva, Maiorana, Arianna, Dionisi-Vici, Carlo, Moeslinger, Dorothea, Brunner-Krainz, Michaela, Lotz-Havla, Amelie Sophia, Cocho de Juan, José Angel, Couce Pico, Maria Luz, Santer, René, Scholl-Bürgi, Sabine, Mandel, Hanna, Bliksrud, Yngve Thomas, Freisinger, Peter, Aldamiz-Echevarria, Luis Jose, Hochuli, Michel, Gautschi, Matthias, Endig, Jessica, Jordan, Jens, McKiernan, Patrick, Ernst, Stefanie, Morlot, Susanne, Vogel, Arndt, Sander, Johannes, Das, Anibh Martin · 2014 · Orphanet Journal of Rare Diseases

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 4 of the 49 sources its claims cite were checked for support.

Abstract

BACKGROUND: Hepatorenal tyrosinaemia (Tyr 1) is a rare inborn error of tyrosine metabolism. Without treatment, patients are at high risk of developing acute liver failure, renal dysfunction and in the long run hepatocellular carcinoma. The aim of our study was to collect cross-sectional data. METHODS: Via questionnaires we collected retrospective data of 168 patients with Tyr 1 from 21 centres (Europe, Turkey and Israel) about diagnosis, treatment, monitoring and outcome. In a subsequent consensus workshop, we discussed data and clinical implications. RESULTS: Early treatment by NTBC accompanied by diet is essential to prevent serious complications such as liver failure, hepatocellular carcinoma and renal disease. As patients may remain initially asymptomatic or develop uncharacteristic clinical symptoms in the first months of life newborn mass screening using succinylacetone (SA) as a screening parameter in dried blood is mandatory for early diagnosis. NTBC-treatment has to be combined with natural protein restriction supplemented with essential amino acids. NTBC dosage should be reduced to the minimal dose allowing metabolic control, once daily dosing may be an option in older children and adults in order to increase compliance. Metabolic control is judged by SA (below detection limit) in dried blood or urine, plasma tyrosine (<400 μM) and NTBC-levels in the therapeutic range (20-40 μM). Side effects of NTBC are mild and often transient. Indications for liver transplantation are hepatocellular carcinoma or failure to respond to NTBC. Follow-up procedures should include liver and kidney function tests, tumor markers and imaging, ophthalmological examination, blood count, psychomotor and intelligence testing as well as therapeutic monitoring (SA, tyrosine, NTBC in blood). CONCLUSION: Based on the data from 21 centres treating 168 patients we were able to characterize current practice and clinical experience in Tyr 1. This information could form the basis for clinical practice recommendations, however further prospective data are required to underpin some of the recommendations.

Overview

CoChat Summary

## TL;DR

This retrospective cross-sectional survey of 168 patients with tyrosinaemia type 1 (Tyr 1) from 21 centres aimed to describe diagnosis, treatment, monitoring, and outcomes, then use a consensus workshop to derive clinical implications. The paper argues that newborn screening using succinylacetone (SA), early NTBC plus diet, and structured follow-up are key to reducing severe complications, especially hepatocellular carcinoma (HCC).

## Key findings

  • Among 168 patients, 132 were diagnosed by selective screening and only 28 by newborn screening (NBS); the average age at diagnosis was 12.9 months overall, 0.58 months in NBS-diagnosed patients, and 15.5 months in selectively screened patients.
  • Delayed NTBC treatment was associated with substantially higher HCC risk: treatment started at 1–6 months carried a 2.5-fold risk, 7–12 months a 6-fold risk, and beyond 12 months a 13-fold risk compared with treatment started in the neonatal period.
  • 29/168 patients underwent liver transplantation; the main indication was HCC (72% of transplants), with liver cirrhosis and liver failure also listed as indications.
  • The cohort had frequent complications despite treatment: 20% had psychomotor impairment, 17 patients (11.5%) required special education, and the paper reports that acute liver failure was rare (5/148 treated patients) when treatment was late (>6 months), while early-treated patients had few sequelae.

## Methods

  • Retrospective cross-sectional international survey using questionnaires sent to 22 metabolic centres in Europe, Turkey, and Israel; 21 centres contributed individual patient data.
  • Data were collected on 168 patients with Tyr 1, covering demographics, diagnosis, treatment, monitoring, liver transplantation, side effects, and outcomes; a 2-day consensus workshop in Hannover (November 2012) discussed findings and clinical implications.
  • Analysis was largely descriptive, with age-dependency and treatment-outcome associations tested using chi-squared/Fisher’s exact tests, plus odds ratios and confidence intervals; continuous lab values were analyzed with ANOVA, Kruskal-Wallis, or Mann-Whitney U as appropriate.

## Limitations

  • The paper explicitly states that further prospective data are required to underpin some recommendations and that prospective studies are needed to confirm suggested target values and outcome relations.
  • As a retrospective questionnaire study, the paper could not establish causality and notes at least one unavailable element: compliance with medication was not addressed in the questionnaire.
  • Evident from the text: practices varied considerably across centres in diagnosis, treatment, and monitoring, which limits uniform interpretation and reflects heterogeneity rather than a controlled protocol.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13023-014-0107-7

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Tyrosine metabolism.
Figure 1 Tyrosine metabolism.CC BY · PubMed Central
Figure 2 Distribution of patients according to diagnostic procedure.
Figure 2 Distribution of patients according to diagnostic procedure.CC BY · PubMed Central
Figure 3 Initial symptoms are age-dependent. a-i: Age-dependency of initial symptoms: The most common symptoms like renal tubular dysfunction, nephromegaly, growth retardation, rickets, liver dysfunction and carcinoma and the combination of symptoms are depicted. *significant difference (p <0.05) vs < 2 months. n: <2 m =34 patients, 2-6 m = 43 patients, >6 m =61 patients.
Figure 3 Initial symptoms are age-dependent. a-i: Age-dependency of initial symptoms: The most common symptoms like renal tubular dysfunction, nephromegaly, growth retardation, rickets, liver dysfunction and carcinoma and the combination of symptoms are depicted. *significant difference (p <0.05) vs < 2 months. n: <2 m =34 patients, 2-6 m = 43 patients, >6 m =61 patients.CC BY · PubMed Central
Figure 4 The frequency of complications depends on the age at start of NTBC-treatment. a-g: Age at initiation of NTBC treatment and frequency of complications: The most common complications like liver disease, HCC,renal dysfunction, rickets and necessity of liver transplantation are shown. *significant difference (p <0.05) vs < 1 month. n: < 1 m =37 patients; 1-6 m =45 patients; 7-12 m =20 patients; >13 m =46 patients.
Figure 4 The frequency of complications depends on the age at start of NTBC-treatment. a-g: Age at initiation of NTBC treatment and frequency of complications: The most common complications like liver disease, HCC,renal dysfunction, rickets and necessity of liver transplantation are shown. *significant difference (p <0.05) vs < 1 month. n: < 1 m =37 patients; 1-6 m =45 patients; 7-12 m =20 patients; >13 m =46 patients.CC BY · PubMed Central
Figure 5 Differences in dietary treatment. Phe = Phenylalanine; Tyr = Tyrosine.
Figure 5 Differences in dietary treatment. Phe = Phenylalanine; Tyr = Tyrosine.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 1 Not valid · 29 Not checked · 141 Own results and interpretations

86 more claims

Create a free account to see all 175 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 48
  • It may state two separate claims as one. 50
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 60 references

Cited by

See all 133

Metadata

Authors
Mayorandan, S., Meyer, U., Gokcay, G., Segarra, N. G., de Baulny, H. O., van Spronsen, F., Zeman, J., de Laet, C., Spiekerkoetter, U., Thimm, E., Maiorana, A., Dionisi-Vici, C., Moeslinger, D., Brunner-Krainz, M., Lotz-Havla, A. S., Cocho de Juan, J. A., Couce Pico, M. L., Santer, R., Scholl-Bürgi, S., Mandel, H., Bliksrud, Y. T., Freisinger, P., Aldamiz-Echevarria, L. J., Hochuli, M., Gautschi, M., Endig, J., Jordan, J., McKiernan, P., Ernst, S., Morlot, S., Vogel, A., Sander, J., & Das, A. M.
Affiliations
  • Medizinische Hochschule Hannover (DE)
  • Charles University (CZ)
  • University Medical Center Freiburg (DE)
  • Düsseldorf University Hospital (DE)
  • Bambino Gesù Children's Hospital (IT)
  • Ludwig-Maximilians-Universität München (DE)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Rambam Health Care Campus (IL)
  • Oslo University Hospital (NO)
  • Klinik und Poliklinik für Kinder- und Jugendmedizin (DE)
  • Hospital de Cruces (ES)
  • University Hospital Zurich (CH)
  • University Hospital of Bern (CH)
  • Birmingham Children's Hospital (GB)
Corresponding author
Das, Anibh Martin
Venue
Orphanet Journal of Rare Diseases
Published
2014-08-01
Volume
9
Issue
1
Pages
107-107
ISSN
1750-1172 (ISSN-L)
OpenAlex
W2145611140
Cited by
131
References
60
Citations by year
2026: 1 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 16 · 2021: 18 · 2020: 11 · 2019: 10 · 2018: 11 · 2017: 22 · 2016: 9 · 2015: 8 · 2014: 3
FWCI
9.64
Type
journal article
Language
en
Open access
Locations
  • Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • BORIS (University Library Bern) (submittedVersion, cc-by)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
  • RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
  • Open Access CRIS of the University of Bern
Funders
Medizinischen Hochschule Hannover
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
nitisinone, NTBC, succinylacetone, newborn screening, protein restriction, essential amino acids, hepatocellular carcinoma, liver transplantation, acute liver failure, renal dysfunction, plasma tyrosine, therapeutic monitoring, medication adherence, clinical guidelines
MeSH terms
Adolescent, Child, Child, Preschool, Cross-Sectional Studies, Cyclohexanones, Enzyme Inhibitors, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Nitrobenzoates, Surveys and Questionnaires, Retrospective Studies, Neonatal Screening, Liver Transplantation, Treatment Outcome, Liver Failure, Tyrosinemias, Rare Diseases, Renal Insufficiency, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. https://app.cochat.ai/papers/10.1186/s13023-014-0107-7
The paper
Mayorandan, S., Meyer, U., Gokcay, G., Segarra, N. G., de Baulny, H. O., van Spronsen, F., Zeman, J., de Laet, C., Spiekerkoetter, U., Thimm, E., Maiorana, A., Dionisi-Vici, C., Moeslinger, D., Brunner-Krainz, M., Lotz-Havla, A. S., Cocho de Juan, J. A., Couce Pico, M. L., Santer, R., Scholl-Bürgi, S., . . . Das, A. M. (2014). Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-014-0107-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.